H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma

Diffuse midline glioma is the leading cause of solid cancer-related deaths in children with very limited treatment options. A majority of the tumors carry a point mutation in the histone 3 variant (H3.3) creating a potential HLA-A*02:01 binding epitope (H3.3K27M(26-35)). Here, we isolated an H3.3K27...

Descripción completa

Detalles Bibliográficos
Autores principales: Immisch, Lena, Papafotiou, George, Popp, Oliver, Mertins, Philipp, Blankenstein, Thomas, Willimsky, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621174/
https://www.ncbi.nlm.nih.gov/pubmed/36302563
http://dx.doi.org/10.1136/jitc-2022-005535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621174/
https://www.ncbi.nlm.nih.gov/pubmed/36302563
http://dx.doi.org/10.1136/jitc-2022-005535

Ejemplares similares